SC-005 / AbbVie 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  SC-005 / AbbVie
    Journal:  Antibacterial Activity and Cytotoxicity Screening of Acyldepsipeptide-1 Analogues Conjugated to Silver/Indium/Sulphide Quantum Dots. (Pubmed Central) -  Feb 23, 2024   
    ADEP1 analogues (SC005-8) conjugated to gelatin-capped Silver/Indium/Sulfide (AgInS2) quantum dots (QDs) improved the antibacterial activity against Gram-negative (Escherichia coli and Pseudomonas aeruginosa), and Gram-positive (Bacillus subtilis, Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus) bacteria...The AgInS2-ADEP1 analogue conjugates were non-toxic against HEK-293 cells at concentrations that showed antibacterial activity. The findings reported herein could be helpful in the development of antibacterial treatment strategies.
  • ||||||||||  SC-005 / AbbVie
    SC005 - Technology & Health in the Stroke Field (Stroke Central, Learning Studio 2, Hall C, Booth 647) -  Feb 22, 2022 - Abstract #ISC2022ISC_1317;    
    The findings reported herein could be helpful in the development of antibacterial treatment strategies. In this session, we will be discussing:- telehealth/telestroke – how it changed the medical field, what to expect in the future- how do we help the less-privileged community, who might not have easy access to the internet, also access to telestroke in rural centers for acute stroke care- Telemedicine for routine care, clinic side, how does the affect the patient relationship- Mobile stroke unit and advancing early stroke care in the field- Social media in neurology – where to turn, how to use it, what to trust, how has it changed the way patients view their care, any harms?
  • ||||||||||  SC-005 / AbbVie
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) -  Dec 17, 2018   
    P1,  N=2, Terminated, 
    In this session, we will be discussing:- telehealth/telestroke – how it changed the medical field, what to expect in the future- how do we help the less-privileged community, who might not have easy access to the internet, also access to telestroke in rural centers for acute stroke care- Telemedicine for routine care, clinic side, how does the affect the patient relationship- Mobile stroke unit and advancing early stroke care in the field- Social media in neurology – where to turn, how to use it, what to trust, how has it changed the way patients view their care, any harms? N=108 --> 2 | Trial completion date: Dec 2021 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2021 --> Oct 2018; Strategic considerations
  • ||||||||||  SC-005 / AbbVie
    Trial completion date:  A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) -  Mar 3, 2018   
    P1,  N=108, Recruiting, 
    N=108 --> 2 | Trial completion date: Dec 2021 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2021 --> Oct 2018; Strategic considerations Trial completion date: Oct 2021 --> Dec 2021